The U.S. Food and Drug Administration has approved Moderna's mRNA-based influenza vaccine, mFlusiva, marking a significant advancement in flu prevention, especially for adults aged 65 and older. Clinical trials demonstrated that mFlusiva generated a stronger immune response compared to conventional egg-based flu shots, offering improved protection against circulating strains.
According to the Centers for Disease Control and Prevention, flu vaccines have historically reduced the risk of illness by 40% to 60% when well-matched to circulating viruses, but effectiveness drops significantly in older adults due to age-related immune decline.
Dr. Elena Ruiz, an infectious disease specialist at Nassau University Medical Center, said, 'The science behind mFlusiva is promising and represents a real step forward in protecting our seniors.' She added that early data suggests better antibody durability, which could translate to fewer hospitalizations during peak flu season.
Despite the medical progress, doctors across Long Island warn that historical patterns of vaccine skepticism, particularly following the COVID-19 pandemic, may deter patients from seeking the new shot. Misinformation about mRNA technology persists in some communities, and outreach efforts have not kept pace with the need for education.
Access remains another concern, especially in underserved areas of Suffolk County where clinic hours are limited and transportation barriers exist. Public health officials stress that without targeted engagement through trusted local leaders and multilingual messaging, uptake could lag even among those most vulnerable to severe flu outcomes.
Looking ahead, state health departments plan to distribute mFlusiva through pharmacies and senior centers starting in September, ahead of the typical flu season peak. Success will depend not only on vaccine availability but on rebuilding public trust in immunization programs after years of polarization.
Evergreen background: Influenza causes tens of thousands of deaths annually in the United States, with older adults accounting for the majority of hospitalizations and fatalities. Annual vaccination remains the most effective preventive measure, though traditional methods have faced challenges in keeping up with viral mutations and aging immune systems.
mRNA Technology Offers New Hope for Flu Prevention
The approval of mFlusiva builds on the success of mRNA platforms during the pandemic, adapting the technology to influenza—a virus that mutates rapidly and requires frequent vaccine updates. Unlike traditional methods that rely on growing virus in eggs, mRNA vaccines can be designed and produced more quickly, allowing for better strain matching.
Experts note that while no vaccine is 100% effective, mRNA-based flu shots could improve protection rates, particularly in populations that respond poorly to conventional vaccines. Ongoing studies are evaluating whether this approach can reduce flu-related complications like pneumonia and heart events in high-risk groups.
Key questions
- What is mFlusiva and how is it different from traditional flu shots?
- mFlusiva is Moderna's mRNA-based influenza vaccine approved by the FDA for adults aged 65 and older. Unlike traditional flu shots that grow virus in chicken eggs, mFlusiva uses messenger RNA technology to instruct cells to produce an immune response, potentially offering faster development and stronger protection in older adults with weaker immune systems.
- Why are Long Island doctors concerned about low uptake of the new mRNA flu shot?
- Doctors on Long Island worry that vaccine hesitancy fueled by misinformation, lingering skepticism from the COVID-19 pandemic, and limited access in underserved areas may prevent many older adults from getting mFlusiva, despite its improved efficacy, leaving vulnerable populations at risk during flu season.
